Priority area lead: Dr Richard Bryan, Cancer Sciences, r.t.bryan@bham.ac.uk
Please note: whereas our other priority areas should be considered a guide, Uro-Oncology has received specific funding for one Birmingham Fellowship in this field.
We are seeking a talented basic science researcher with an excellent track record to take up a prestigious Birmingham Fellowship linked to the Uro-Oncology Group in the University of Birmingham School of Cancer Sciences. The University is host to the first Cancer Research UK Centre, has been designated as a ‘Centre of Excellence’ by Leukaemia and Lymphoma Research, and represents one of the world’s premier translational cancer research centres. Our portfolio is broad and ranges from leading research in NMR spectroscopy through to large clinical trials that improve the outlook for cancer patients.
We are looking for a researcher with a particular interest in cancer cell signalling and the identification of novel potential therapeutic targets. The applicant should have significant post-doctoral experience that demonstrates clear progression towards independence. Applicants without a uro-oncology background are encouraged to apply, but they should have an interest in pursuing research in this area. The Uro-Oncology Group has an excellent track record in basic science research, epidemiological studies, and clinical trials, with the core team comprised of a Professor of Oncology, a Professor of Epidemiology, two Senior Lecturers in Urology, a Senior Research Fellow in Urology, and a Laboratory Technician, as well as a number of internal and external collaborators. The basic science interests of the Uro-Oncology Group are:
-
Bladder cancer: cell adhesion, invasion, metastasis, angiogenesis, genomics, epigenomics, and biomarker discovery
-
Prostate cancer: Wnt signalling, autotaxin and immunotherapy, and gene therapy
-
Kidney cancer: Immunology, lipid signalling, and VHL mutation.